#USA #Skincare #Nashville #Revance #AAD

Revance Showcases Aesthetics and Skincare Innovations at the 2026 AAD Annual Meeting

NASHVILLE, Tenn., March 25, 2026 /PRNewswire/ -- Revance, a rapidly expanding global player in aesthetics, regenerative solutions, and consumer skincare, is set to unveil a variety of ground-breaking innovations at the American Academy of Dermatology (AAD) Annual Meeting happening from March 27–31, 2026, in Denver, Colorado. This year, Revance will engage the dermatology community through educational sessions and networking activities, reinforcing its dedication to the field.

"We are thrilled to present our advancements at AAD this year, showcasing the strides Revance has made within our aesthetics, regenerative, and skincare lineup," said Nadeem Moiz, CEO of Revance. He emphasized the company's mission to push boundaries in dermatology through science-driven innovations that open new clinical avenues. "This annual gathering offers a fantastic platform for us to connect with dermatology professionals, share ideas, and spotlight new advancements that are paving the future of aesthetic and skin health care. Moreover, we are excited to collaborate with Dr. Bhanusali, Dr. Shah, and the AIRE Health team to enhance awareness around our skincare offerings that support both the dermatology community and its clientele."

During the conference, Revance will work closely with AIRE Health—a pioneering platform initiated by dermatologists Dr. Dhaval Bhanusali and Dr. Muneeb Shah—to educate attendees on the evolving partnership between physicians and brands. Special invite-only receptions will also be held at an external venue in Denver, allowing for networking among top dermatologists, innovators, and business partners.

Furthermore, Revance is organizing booth discussions led by eminent dermatology authorities who will share insights on new trends and clinical knowledge regarding the company's diverse aesthetics portfolio. Notable speakers include:

• - Diane Berson, MD: Discussing DAXXIFY® and the Teoxane RHA® Collection (Friday, 3/27 at 12:00 PM)
• - Michael Gold, MD: Insights on SkinPen® microneedling devices (Friday, 3/27 at 12:30 PM)
• - Ava Shamban, MD: Focus on DAXXIFY® (Saturday, 3/28 at 12:00 PM)
• - Jody Comstock, MD: Discussing the Teoxane RHA® Collection and the Teoxane MLT Multilayering Technique™ (Saturday, 3/28 at 12:30 PM)
• - Suneel Chilukuri, MD, FAAD, FACMS: Exploring SkinPen® (Saturday, 3/28 at 1:00 PM)

Revance will also highlight its latest consumer skincare advancements, showcasing products under the PanOxyl® brand, including the Antimicrobial Purifying Mist, Acne Cleansing Bar, Acne Gel Wash, and the Blue Lizard® After Sun Soothing Lotion, among others. Attendees can expect to receive samples of these new skincare solutions, along with some of the company’s flagship products, during the event.

In addition, dermatologists can take advantage of the opportunity to order exclusive Blue Lizard scrub tops during the Exhibit Hall openings, while supplies last.

Conference attendees are invited to visit Revance at Booth #3732 to explore the company’s innovations and anticipated developments across its entire portfolio in aesthetics, regenerative, and consumer skincare. To learn more about Revance and its offerings, please visit Revance.com.

About Revance

Revance is a global innovator in aesthetics, skincare, and therapeutics, dedicated to producing and distributing a range of unique treatments. The company aims to reshape the standards in aesthetics and skin care through cutting-edge research and innovation. Committed to providing exceptional service to healthcare providers, patients, and consumers alike, Revance's award-winning products emerge from extensive R&D backed by world-renowned scientists. For further details about Revance, visit us at www.revance.com.

IMPORTANT SAFETY INFORMATION for DAXXIFY® (daxibotulinumtoxinA-Ianm): DAXXIFY® may induce serious side effects potentially leading to life-threatening complications. Seek immediate medical assistance if experiencing swallowing, speaking, or breathing difficulties after the injection of DAXXIFY®. Symptoms can persist for several months. Other contraindications include severe allergic reactions and prior allergic responses to botulinum toxin products. Patients should communicate with their healthcare provider about their medical history and the use of any medications to avoid serious side effects. Refer to prescribing information for further details.

DAXI-001723.2